{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"90.9","upperLimit":"99.5","value":"97.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"67"}],"units":"Participants"}],"description":"ORR was defined as the percentage of participants who achieved a PR or better, IMWG criteria, during the study or during follow up. IMWG criteria for PR \\>= 50% reduction of serum M-protein and reduction in 24 hour urinary M-protein by \\>=90% or to \\<200 mg/24 hours, if the serum and urine M-protein are not measurable, a decrease of \\>=50% in the difference between involved and uninvolved FLC levels is required in place of the M-protein criteria, If serum and urine M-protein are not measurable, and serum free light assay is also not measurable, \\>=50% reduction in bone marrow PCs is required in place of M-protein, provided baseline bone marrow plasma cell percentage was \\>=30%, in addition to the above criteria, if present at baseline, a \\>=50% reduction in the size of soft tissue plasmacytomas is also required.","dispersionType":"90% Confidence Interval","groups":[{"description":"Participants received daratumumab 1800 milligrams (mg) as a subcutaneous (SC) injection on Days 1, 8 and 15 of Cycles 1 to 3 (each cycle of 21 days) and on Day 1 of Cycle 4; bortezomib 1.3 milligrams per square meter (mg/m\\^2) SC injection on Days 1, 4, 8 and 11 of Cycles 1 to 4; lenalidomide 25 mg orally on Day 1 through Day 14 of Cycles 1 to 4 and dexamethasone 20 mg orally or intravenously (IV) on Days 1, 2 ,8, 9, 15 and 16 of Cycle 1 to 4.","id":"OG000","title":"Daratumumab (D)+Bortezomib+Lenalidomide+Dexamethasone (D-VRd)"}],"paramType":"NUMBER","populationDescription":"All treated analysis set included all participants who have received at least 1 dose of study treatment. This secondary OM was planned to be analyzed for D-VRd cohort only.","reportingStatus":"POSTED","timeFrame":"Up to 2 years and 3 months","title":"D-VRd Cohort: Overall Response Rate (ORR)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}